繁體
  • 简体中文
  • 繁體中文
×

熱門資訊> 正文

Pacira报告25财年初步收入为7.264亿美元

2026-01-09 05:23

  • Pacira BioSciences (PCRX) on Thursday reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024.
  • The company also repurchased 2M shares of its common stock during the fourth quarter.
  • Consensus for annual revenue is $730.22M.
  • The company sees fourth quarter EXPAREL net product sales of $155.8 million in 2025, compared with $147.7 million in 2024. 
  • Fourth quarter ZILRETTA net product sales of $33.0 million in 2025, compared with $33.1 million in 2024.
  • Fourth quarter iovera net product sales of $7.0 million in 2025, compared with $6.5 million in 2024.
  • Other revenue, comprised of sales of bupivacaine liposome injectable suspension, was $1.1 million in the fourth quarter of 2025, compared with zero in the fourth quarter of 2024.
  • Preliminary Unaudited Full-Year Revenue Highlights: 
  • Full-year EXPAREL net product sales of $575.1 million in 2025, compared with $549.0 million in 2024. Full-year volume growth of 6 percent was partially offset by a shift in vial mix and discounting associated with the company’s new GPO partnerships.
  • Full-year ZILRETTA net product sales of $116.6 million in 2025, compared with $118.1 million in 2024.
  • Full-year iovera° net product sales of $24.2 million in 2025, compared with $22.8 million in 2024.
  • Other revenue, comprised of sales of bupivacaine liposome injectable suspension and royalties, was $10.5 million in 2025, compared with $11.1 million in 2024.
  • PCRX --3.92% after hours to $25.0.
  • Source: Press Release

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
（工作日09：30 - 次日05：30）
客戶端：
關注我們：
  • 微信公眾號二維碼

© 2026 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號